A PHASE II OPEN LABEL, MULTI-CENTER CLINICAL TRIAL TO EVALUATE SAFETY AND EFFICACY OF ORAL WCK 2349 (1000 mg BID and 1200 mg BID) IN THE TREATMENT OF COMPLICATED SKIN AND SOFT TISSUE INFECTIONS CAUSED BY GRAM POSITIVE BACTERIA, INCLUDING METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS.

Trial Profile

A PHASE II OPEN LABEL, MULTI-CENTER CLINICAL TRIAL TO EVALUATE SAFETY AND EFFICACY OF ORAL WCK 2349 (1000 mg BID and 1200 mg BID) IN THE TREATMENT OF COMPLICATED SKIN AND SOFT TISSUE INFECTIONS CAUSED BY GRAM POSITIVE BACTERIA, INCLUDING METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Aug 2016

At a glance

  • Drugs Alalevonadifloxacin (Primary)
  • Indications Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Nov 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top